CHRONIC HEPATITIS C
Clinical trials for CHRONIC HEPATITIS C explained in plain language.
Never miss a new study
Get alerted when new CHRONIC HEPATITIS C trials appear
Sign up with your email to follow new studies for CHRONIC HEPATITIS C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hepatitis c relapse: triple therapy aims for cure
⭐️ CURE ⭐️ CompletedThis study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 108 adults with genotype 2 hepatitis C whose previous treatment failed. The goal was to see if this combination could clear the virus completely, measured by…
Matched conditions: CHRONIC HEPATITIS C
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: ⭐️ CURE ⭐️
Last updated May 15, 2026 11:56 UTC
-
New hepatitis c drug shows promise in early safety trial
Disease control CompletedThis early-stage study tested a single dose of the experimental drug MP-424 in 10 people with chronic hepatitis C (genotype 1b). The main goals were to check the drug's safety and how it behaves in the body. Researchers also measured how the drug affected hepatitis C virus levels…
Matched conditions: CHRONIC HEPATITIS C
Phase: PHASE1 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 17, 2026 07:35 UTC
-
Vitamin d boost may help Hard-to-Treat hepatitis c patients
Disease control CompletedThis study looked at whether giving vitamin D supplements to people with chronic hepatitis C (genotypes 1 or 4) who had not responded to earlier treatment could improve the effectiveness of a standard antiviral therapy. 32 adults with low vitamin D levels received vitamin D along…
Matched conditions: CHRONIC HEPATITIS C
Phase: PHASE2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated May 17, 2026 07:35 UTC
-
New hope for hepatitis c relapse: triple therapy shows promise
Disease control CompletedThis study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 109 adults with genotype 1 hepatitis C whose infection returned after previous treatment. The goal was to see if this combination could make the virus undete…
Matched conditions: CHRONIC HEPATITIS C
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 17, 2026 07:31 UTC
-
Can a higher dose of a common liver drug help hepatitis c patients?
Disease control CompletedThis study tested whether taking a higher dose of ursodeoxycholic acid (UDCA) for 24 weeks could improve liver health in 596 adults with chronic hepatitis C. Participants received either 150 mg, 600 mg, or 900 mg of UDCA daily. The main goal was to see if higher doses lowered liv…
Matched conditions: CHRONIC HEPATITIS C
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 17, 2026 07:31 UTC
-
New hope for hard-to-treat hepatitis c: experimental combo targets non-responders
Disease control CompletedThis study tested a new drug called MP-424 combined with two standard hepatitis C medications (peginterferon alfa-2b and ribavirin) in 10 adults with genotype 2 hepatitis C who had not responded to earlier treatment. The main goal was to see if the virus could be cleared from the…
Matched conditions: CHRONIC HEPATITIS C
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 11, 2026 20:40 UTC